MTOR and non-small cell lung carcinoma: The results demonstrated that metformin combined with PD-L1 MAb could significantly inhibit the viability of LLC cells, increase the release of cytokines, and the expression of p-AMPK and mTOR in cells, and the results proved that the anti-tumor action of metformin with PD-L1 MAb on NSCLC was AMPK-dependent.